Annual EBITDA
-$114.27 M
-$96.45 M-541.33%
31 December 2023
Summary:
Repare Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$114.27 million, with the most recent change of -$96.45 million (-541.33%) on 31 December 2023. During the last 3 years, it has fallen by -$60.87 million (-113.97%). RPTX annual EBITDA is now -1781.66% below its all-time high of -$6.07 million, reached on 31 December 2017.RPTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$34.37 M
+$2.46 M+6.69%
30 September 2024
Summary:
Repare Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$34.37 million, with the most recent change of +$2.46 million (+6.69%) on 30 September 2024. Over the past year, it has increased by +$3.55 million (+9.37%). RPTX quarterly EBITDA is now -146.52% below its all-time high of $73.88 million, reached on 30 September 2022.RPTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$90.24 M
+$3.55 M+3.79%
30 September 2024
Summary:
Repare Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$90.24 million, with the most recent change of +$3.55 million (+3.79%) on 30 September 2024. Over the past year, it has increased by +$12.85 million (+12.46%). RPTX TTM EBITDA is now -1135.60% below its all-time high of $8.71 million, reached on 30 June 2023.RPTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -541.3% | +9.4% | +12.5% |
| 3 y3 years | -114.0% | -9.8% | +5.6% |
| 5 y5 years | -820.6% | -411.9% | -427.2% |
RPTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -541.3% | at low | -146.5% | +10.1% | -1135.6% | +31.7% |
| 5 y | 5 years | -820.6% | at low | -146.5% | +10.1% | -1135.6% | +31.7% |
| alltime | all time | -1781.7% | at low | -146.5% | +10.1% | -1135.6% | +31.7% |
Repare Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$34.37 M(-6.7%) | -$90.24 M(-3.8%) |
| June 2024 | - | -$36.83 M(-425.4%) | -$93.80 M(+36.5%) |
| Mar 2024 | - | $11.32 M(-137.3%) | -$68.72 M(-39.9%) |
| Dec 2023 | -$114.27 M(+541.3%) | -$30.36 M(-19.9%) | -$114.27 M(+10.8%) |
| Sept 2023 | - | -$37.92 M(+222.7%) | -$103.09 M(-1283.0%) |
| June 2023 | - | -$11.75 M(-65.7%) | $8.71 M(-149.1%) |
| Mar 2023 | - | -$34.24 M(+78.5%) | -$17.75 M(-0.4%) |
| Dec 2022 | -$17.82 M(-83.4%) | -$19.18 M(-126.0%) | -$17.82 M(-34.0%) |
| Sept 2022 | - | $73.88 M(-293.4%) | -$27.01 M(-79.6%) |
| June 2022 | - | -$38.21 M(+11.4%) | -$132.20 M(+9.9%) |
| Mar 2022 | - | -$34.31 M(+21.0%) | -$120.24 M(+12.2%) |
| Dec 2021 | -$107.19 M | -$28.37 M(-9.4%) | -$107.19 M(+12.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$31.31 M(+19.3%) | -$95.61 M(+22.3%) |
| June 2021 | - | -$26.25 M(+23.5%) | -$78.18 M(+22.1%) |
| Mar 2021 | - | -$21.26 M(+26.6%) | -$64.04 M(+19.9%) |
| Dec 2020 | -$53.41 M(+107.2%) | -$16.79 M(+21.0%) | -$53.41 M(+18.0%) |
| Sept 2020 | - | -$13.88 M(+14.6%) | -$45.27 M(+18.8%) |
| June 2020 | - | -$12.12 M(+14.1%) | -$38.10 M(+20.1%) |
| Mar 2020 | - | -$10.62 M(+22.7%) | -$31.73 M(+23.1%) |
| Dec 2019 | -$25.77 M(+107.6%) | -$8.66 M(+28.9%) | -$25.77 M(+50.6%) |
| Sept 2019 | - | -$6.71 M(+16.9%) | -$17.12 M(+64.5%) |
| June 2019 | - | -$5.75 M(+23.4%) | -$10.40 M(+123.4%) |
| Mar 2019 | - | -$4.66 M | -$4.66 M |
| Dec 2018 | -$12.41 M(+104.4%) | - | - |
| Dec 2017 | -$6.07 M | - | - |
FAQ
- What is Repare Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Repare Therapeutics?
- What is Repare Therapeutics annual EBITDA year-on-year change?
- What is Repare Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Repare Therapeutics?
- What is Repare Therapeutics quarterly EBITDA year-on-year change?
- What is Repare Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Repare Therapeutics?
- What is Repare Therapeutics TTM EBITDA year-on-year change?
What is Repare Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of RPTX is -$114.27 M
What is the all time high annual EBITDA for Repare Therapeutics?
Repare Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$6.07 M
What is Repare Therapeutics annual EBITDA year-on-year change?
Over the past year, RPTX annual earnings before interest, taxes, depreciation & amortization has changed by -$96.45 M (-541.33%)
What is Repare Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of RPTX is -$34.37 M
What is the all time high quarterly EBITDA for Repare Therapeutics?
Repare Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $73.88 M
What is Repare Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RPTX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$3.55 M (+9.37%)
What is Repare Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of RPTX is -$90.24 M
What is the all time high TTM EBITDA for Repare Therapeutics?
Repare Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $8.71 M
What is Repare Therapeutics TTM EBITDA year-on-year change?
Over the past year, RPTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$12.85 M (+12.46%)